Figures & data
Table 1 Preparation of MMF-Loaded βCD Nanoparticles Using Varying Ratios of βCD and Stearic Acid to MMF
Table 2 Composition of Selected Formulation for the Preparation of MMF-Loaded βCD Nanoparticles
Figure 1 FTIR spectra of (A) MMF, (B) stearic acid, (C) βCD and (D) MMF-loaded βCD facilitated SLNs, describing the chemical compatibilities of selected the ingredients.
![Figure 1 FTIR spectra of (A) MMF, (B) stearic acid, (C) βCD and (D) MMF-loaded βCD facilitated SLNs, describing the chemical compatibilities of selected the ingredients.](/cms/asset/bc8e4470-bb72-4d5a-adc2-82271262d032/dijn_a_12194694_f0001_b.jpg)
Figure 3 SEM micrograph of MMF-loaded βCD facilitated SLNs, illustrating nanosized particles with smooth spherical shape.
![Figure 3 SEM micrograph of MMF-loaded βCD facilitated SLNs, illustrating nanosized particles with smooth spherical shape.](/cms/asset/025fa3d0-ae43-4171-890d-3d01a7f8748e/dijn_a_12194694_f0003_b.jpg)
Figure 4 Calibration curve for MMF, describing linearity behavior in the selected range of concentration (2–12 µg/mL) at 254 nm.
![Figure 4 Calibration curve for MMF, describing linearity behavior in the selected range of concentration (2–12 µg/mL) at 254 nm.](/cms/asset/adda1c8a-646f-42b9-ba07-859563f30bd4/dijn_a_12194694_f0004_c.jpg)
Figure 6 Graphical representation of in vitro drug release, conducted at acidic pH (1.2) and basic pH (7.2), showing sustained and controlled release of drug from MMF-loaded βCD facilitated SLNs, during 12 h of the studies.
![Figure 6 Graphical representation of in vitro drug release, conducted at acidic pH (1.2) and basic pH (7.2), showing sustained and controlled release of drug from MMF-loaded βCD facilitated SLNs, during 12 h of the studies.](/cms/asset/24f4986d-6bd1-4beb-894e-024c8dd73d39/dijn_a_12194694_f0006_b.jpg)
Table 3 Kinetic Modeling of the Release Data Obtain from in vitro Dissolution Studies
Figure 7 XRD diffractogram, (A) describing the crystalline nature of the drug, which has also been observed in prepared, (B) MMF-loaded βCD facilitated SLNs, while, (C) also showed some less intense peaks, attributed to crystalline βCD.
![Figure 7 XRD diffractogram, (A) describing the crystalline nature of the drug, which has also been observed in prepared, (B) MMF-loaded βCD facilitated SLNs, while, (C) also showed some less intense peaks, attributed to crystalline βCD.](/cms/asset/c995a5a8-422d-4eb7-b336-32af2ec004e1/dijn_a_12194694_f0007_c.jpg)
Table 4 Outcomes of Statistical Analysis